1. Home
  2. NEOV vs BDSX Comparison

NEOV vs BDSX Comparison

Compare NEOV & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoVolta Inc.

NEOV

NeoVolta Inc.

HOLD

Current Price

$3.17

Market Cap

145.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$15.58

Market Cap

122.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOV
BDSX
Founded
2018
2005
Country
United States
United States
Employees
17
N/A
Industry
Industrial Machinery/Components
Precision Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.6M
122.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NEOV
BDSX
Price
$3.17
$15.58
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
565.2K
75.8K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$88,499,000.00
Revenue This Year
$150.56
$25.26
Revenue Next Year
$5.31
$19.70
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.08
52 Week Low
$1.81
$0.25
52 Week High
$7.13
$20.21

Technical Indicators

Market Signals
Indicator
NEOV
BDSX
Relative Strength Index (RSI) 41.13 52.35
Support Level $2.93 $6.33
Resistance Level $3.80 $20.21
Average True Range (ATR) 0.35 1.25
MACD -0.08 -0.29
Stochastic Oscillator 17.11 42.96

Price Performance

Historical Comparison
NEOV
BDSX

About NEOV NeoVolta Inc.

NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: